Several new studies presented
Tuesday at a major Alzheimer’s conference describe progress in a series of
immune-based therapies that target the tau protein, one of the two major
proteins implicated in Alzheimer’s disease.
As a focus of research, tau protein
‘tangles’ have typically taken a backseat to another protein, the beta amyloid
plaques that proliferate in the brains of people with Alzheimer’s.
However, the new studies suggest
that not only do some tau-focused therapies show promise, some treatments
targeted against beta amyloid also affect tau.
William Thies, chief medical and
scientific officer at the Alzheimer’s Association, called the new results